Company: SCYX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001178253-25-000010
Chunk: 9

Company: SCYNEXIS INC
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 9
---
 Company anticipates receiving Qualified Infectious Disease Product Designation, Orphan Drug Designation and Fast Track Designation which would provide regulatory exclusivity of at least 10 years.The Company had an accumulated deficit of $397.4 million at September 30, 2025.  The Company's capital resources primarily comprised cash and cash equivalents and investments of $37.9 million at September 30, 2025. While the Company believes its capital resources are sufficient to fund the Company’s on-going operations for a period of at least 12 months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements, the Company's liquidity could be materially affected over this period by: (1) its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding; (2) costs associated with new or existing strategic alliances, or licensing and collaboration arrangements; (3) negative regulatory events or unanticipated costs related to its development of SCY-247 and ibrexafungerp; (4) its ability to successfully achieve the regulatory and commercial milestones under its GSK License Agreement; and (5) any other unanticipated material negative events or costs.  One or more of these events or costs could materially affect the Company’s liquidity.  If the Company is unable to meet its obligations when they become due, the Company may have to delay expenditures, reduce the scope of its research and development programs, or make significant changes to its operating plan.  The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.  The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary.  Intercompany balances and transactions are eliminated in consolidation. Nasdaq Minimum Bid Price NotificationOn June 20, 2025, the Company received a letter from the Listing Qualifications Department staff (the "Staff") of the Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock was below the $1.00 per share minimum required for continued listing on the Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(a)(1). The letter from Nasdaq has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Market.In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days from June 20, 2025, or until